|
|
Article: Neurocrine Biosciences Announces the First of Two Presentations of indiplon Data at the American Psychiatric Association (APA) Meeting May 17-22; Results Demonstrate Co-Administration of indiplon and Alcohol Has Little Or No Additive Effect on indiplon When Taken Together.
- Article from:
- PR Newswire
- Article date:
- May 20, 2003
|
Copyright informationCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Neurocrine Biosciences, Inc. announced today that Neurocrine and Clinical Investigators from the Company's indiplon clinical development program presented the first of two abstracts reporting data from a Phase I pharmacokinetic (PK) clinical trial at the American Psychiatric Association (APA) Meeting in San Francisco, May 17-22, 2003.
The first abstract presented late Monday, May 19, 2003 describes the effect of alcohol on the pharmacodynamics (PD) and pharmacokinetics (PK) of a single dose of indiplon (10 mg.) in a randomized, placebo-controlled, double blind, three-way crossover Phase I clinical study in ten healthy adult volunteers. PD assessments of ...
Related newspaper, magazine, and journal articles:
|
|
Article: Shareholders alert for Neurocrine Biosciences Inc.
M2 Presswire;
January 17, 2007 ;
700+ words
......drug candidate Indiplon aims to treat...acquired rights to Indiplon from DOV Pharmaceutical. Neurocrine Biosciences is also developing...needed! Shares of Neurocrine Biosciences Inc. moved higher...earlier-than-expected Indiplon data. The stock...positive mark. ...
|
|